Memantine leading to physical aggression in the treatment of chronic catatonia secondary to schizophrenia: A case report

Memantine leading to physical aggression in the treatment of chronic catatonia secondary to schizophrenia: A case report

Introduction Memantine is a noncompetitive N-methyl-D-aspartate receptor antagonist approved by the FDA for moderate to severe Alzheimer’s dementia. Memantine is also recommended as an off-label treatment in current catatonia clinical guidelines when benzodiazepines alone are inadequate. Case A 37-y...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Chantha Hean, PharmD, Jessica Jones, PharmD, Michael Arena, MD, Kevin Kavanagh, PharmD
Format: Article
Language:English
Published: American Association of Psychiatric Pharmacists 2025-08-01
Series:Mental Health Clinician
Subjects:
memantine
catatonia
benzodiazepine
refractory
schizophrenia
Online Access:https://theijpt.org/doi/pdf/10.9740/mhc.2025.08.218
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items